Anti-epidermal growth factor receptor targeted therapy-associated ulcerations

Area of Science:

• Oncology
• Pharmacology
• Gastroenterology

Background:

• Epidermal growth factor receptor (EGFR) inhibitors, such as panitumumab for metastatic colorectal cancer (mCRC) and osimertinib for non-small cell lung cancer (NSCLC), are crucial targeted therapies.
• Oral adverse events associated with these EGFR inhibitors are underreported and lack standardized characterization in scientific literature.

Discussion:

• This study presents two distinct cases of oral ulcerations linked to panitumumab and osimertinib treatment.
• The discussion emphasizes the potential pathogenesis of these oral toxicities, exploring mechanisms beyond simple mucositis.
• Optimal management strategies for EGFR inhibitor-induced oral ulcerations are highlighted, aiming to improve patient care.

Key Insights:

• Oral ulcerations represent a significant, yet poorly documented, adverse event of EGFR-targeted therapies in mCRC and NSCLC.
• Accurate terminology and detailed reporting are essential for understanding and managing these side effects.
• Early recognition and appropriate intervention can mitigate the impact of oral ulcerations on treatment adherence and quality of life.

Outlook:

• Further research is needed to elucidate the precise mechanisms driving EGFR inhibitor-associated oral ulcerations.
• Development of standardized diagnostic criteria and reporting guidelines for oral toxicities is recommended.
• Clinical trials should prospectively assess the incidence and severity of oral adverse events to inform treatment guidelines.